| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | COVER ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
Dr. Jemal is Program Director, Cancer Occurrence, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Dr. Tiwari is Mathematical Statistician, Statistical Research and Applications Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD.
Mr. Murray is Manager, Surveillance Data Systems, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Ms. Ghafoor is Epidemiologist, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Ms. Samuels is Manager, Surveillance Information Services, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Dr. Ward is Director, Surveillance Research, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
Dr. Feuer is Branch Chief, Statistical Research and Applications Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD.
Dr. Thun is Vice-President, Department of Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA.
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONMATERIALS AND METHODSSELECTED FINDINGSSTUDY LIMITATIONS AND FUTURE...REFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSSELECTED FINDINGSSTUDY LIMITATIONS AND FUTURE...REFERENCES |
|---|
|
MATERIALS AND METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSSELECTED FINDINGSSTUDY LIMITATIONS AND FUTURE...REFERENCES |
|---|
Estimated New Cancer Cases
The precise number of cancer cases diagnosed each year in the nation and in every state is unknown because complete cancer registration has not yet been achieved in many states. Consequently, for the national estimate, we first estimate the number of new cancer cases occurring annually in the United States from 1979 through 2000 by using age-specific cancer incidence rates collected by the SEER program2 coupled with population data reported by the US Census Bureau.6 We then forecast the number of cancer cases expected to be diagnosed in the United States in the year 2004 using an autoregressive quadratic time trend model fitted to the annual cancer case estimates.11 For estimates of new cancer cases in individual states, we relied on state cancer death statistical data and assumed that the ratio of estimated cancer deaths to cases in each state was equal to that in the United States.
Estimated Cancer Deaths
For this report, we used a new method for estimating the number of cancer deaths expected to occur in the United States and in each state in the year 2004. The method is described by Tiwari et al. in an accompanying article in this issue of CA.12 We based our projections on underlying causes of death recorded on death certificates as reported to the National Center for Health Statistics.1 The numbers of cancer deaths recorded annually from 1969 to 2001 in the United States and in each state were fitted using a state-space model to forecast the number of cancer deaths expected to occur in 2004.
Other Statistics
We provide mortality statistics for the leading causes of death and deaths due to cancer in the year 2001. Causes of death for 2001 were coded and classified according to ICD-10.7 This report also provides updated statistics on trends in cancer incidence and mortality rates, probability of developing cancer, and five-year relative survival rates for selected cancer sites based on data from 1973 through 2000.3 All age-adjusted incidence and mortality rates are standardized to the 2000 US standard population and expressed per 100,000 population.
The long-term incidence trends (1975 to 2000) presented in the table are adjusted for delays in reporting. Delayed reporting affects the most recent one to three years of incidence data (in this case, 1998 to 2000) as certain types of cancer continue to be reported. Cancers that are frequently reported late are those diagnosed in outpatient settings, such as melanoma and prostate cancers. The National Cancer Institute has developed a method to account for expected reporting delays for all cancer sites combined and for several specific cancer sites when long-term incidence trends are analyzed.13 Delay-adjusted trends provide a more accurate assessment of trends in the most recent years for which data are available.
|
SELECTED FINDINGS |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSSELECTED FINDINGSSTUDY LIMITATIONS AND FUTURE...REFERENCES |
|---|
|
|
Figure 1 lists the most common cancers expected to occur in men and women in 2004. Among men, cancers of the prostate, lung and bronchus, and colon and rectum account for more than 55% of all newly diagnosed cancers. Prostate cancer alone accounts for approximately 33% (230,110) of incident cases in men. Based on cases diagnosed between 1992 and 1999, approximately 86% of these estimated new cases of prostate cancer are expected to be diagnosed at local or regional stages, for which the five-year relative survival rate equals 100%.
|
The three most commonly diagnosed cancers among women in 2004 will be those of the breast, lung and bronchus, and colon and rectum, accounting for approximately 55% of estimated cancer cases in women. Breast cancer alone is expected to account for 32% (215,990) of all new cancer cases among women.
Expected Numbers of New Cancer Deaths
Table 1 also shows the expected numbers of cancer deaths in 2004 for men, women, and both sexes combined. It is estimated that approximately 563,700 Americans will die of cancer, corresponding to over 1,500 deaths per day. Cancers of the lung and bronchus, prostate, and colon and rectum in men, and cancers of the lung and bronchus, breast, and colon and rectum in women continue to be the most common causes of cancer death. These four cancers account for one half of the total number of cancer deaths among men and women (Figure 1). Lung cancer surpassed breast cancer as the leading cause of cancer death in women in 1987. Lung cancer is expected to account for 25% of all female cancer deaths in 2004. Table 3 provides the estimated number of cancer deaths in 2004 by state for selected cancer sites.
|
Trends in Cancer Incidence and Mortality Rates
Figures 2 to 5
depict long-term trends in cancer incidence and mortality rates for all cancers combined and for selected cancer sites by sex. Table 4 shows incidence and mortality patterns for all cancer sites and for the four common cancer sites based on joinpoint analysis. Trends in incidence were adjusted for delayed reporting in the table, but not in the figures (Figures 2 and 3). Cancer death rates for all cancer sites combined decreased by 1.5% per year from 1992 to 2000 in males, but they stabilized from 1998 to 2000 in females after declining by 1.3% from 1995 to 1998 (Table 4). The leveling of rates among females is in part due to the implementation of ICD-10 rules for coding and selecting the underlying cause of death. Approximately 0.7% more deaths were classified as cancer using ICD-10 rules than using ICD-9 rules,14 creating discontinuity in the most recent cancer mortality rate trend.15,16 Delay-adjusted cancer incidence rates stabilized in men from 1995 to 2000 and increased by 0.4% per year from 1987 to 2000 in women (Table 4).
|
|
|
|
|
Mortality rates have continued to decrease across all four major cancer sites in men and in women (Table 4). The incidence trends are mixed, however. Lung cancer incidence rates are declining in men but still increasing among women, although the rate of increase has slowed. Colorectal cancer incidence rates have stabilized since the mid 1990s in males and females. Female breast and prostate cancer incidence rates have continued to increase, although at a slower rate than in previous years, in part due to increased screening using mammography and prostate-specific antigen testing, respectively. The recent increase in female breast cancer incidence rates involves both small and large tumors, 17which may reflect increased use of hormone replacement therapy, an increased prevalence of obesity, or both.
Changes in the Recorded Number of Deaths Due to Cancer From 2000 to 2001
A total of 553,768 cancer deaths were recorded in the United States in 2001, the most recent year for which actual data are available. Nearly 700 more cancer deaths were recorded in 2001 than in 2000, reflecting growth and aging of the population. Cancer accounted for approximately 23% of all deaths, ranking second only to heart disease (Table 5). When cause of death is ranked within each age group, categorized in 20-year age intervals, cancer ranks as one of the five leading causes of death in each age group among both males and females. Cancer is the leading cause of death among women aged 40 to 79 years and among men aged 60 to 79 years (Table 6). Overall, among men and women combined, cancer is the leading cause of death before age 65, followed by heart disease (Figure 6). A total of 163,546 persons younger than 65 years died of cancer in the United States in 2001, compared with 117,346 persons who died of heart disease.
|
|
|
Table 7 presents the leading site-specific causes of cancer death by age for males and females in 2001. Among men younger than 40 years, leukemia is the most common fatal cancer, whereas cancer of the lung and bronchus predominate in men aged 40 years and older. Colorectal cancer is the second most common fatal cancer among men aged 40 to 79 years, and prostate cancer is the second most common among men aged 80 and older. Among women, the leading causes of cancer death are leukemia among those younger than 20 years, breast cancer among those aged 20 to 59 years, and lung cancer in those 60 years and older.
|
From 2000 to 2001, the number of recorded cancer deaths increased by 993 in men, whereas it decreased by 316 in women. The total number of cancer deaths decreased slightly across all of the four major cancer sites, except for lung cancer in females. Five hundred ninety more women in the United States died of lung cancer in 2001 than in 2000 (Table 8).
|
Cancer Occurrence by Race and Ethnicity
Cancer incidence and mortality rates vary considerably among racial and ethnic groups (Table 9). For all cancer sites combined, African American men have a 25% and 43% higher cancer incidence and mortality rate, respectively, than do White men. African-American women have lower incidence rates than do White females for all cancer sites combined, and yet they have 20% higher mortality rate. For the specific cancer sites listed in Table 9, incidence and mortality rates are consistently higher in African Americans than in Whites, except for breast cancer (incidence) and lung cancer (mortality) among women. Death rates from stomach and cervical cancers among African Americans are more than twice the rates in Whites. Factors that contribute to mortality differences in African Americans and Whites include differences in exposure (eg, hepatitis C for liver cancer), access to regular screening (breast, cervical, and colorectal cancers), and timely, high-quality treatments (many cancers). The higher breast cancer incidence rates among White females are thought to reflect a combination of more frequent mammography, delayed childbearing, and perhaps greater use of hormone replacement therapy.
|
Among other racial and ethnic groups, cancer incidence and mortality rates are lower for all cancer sites combined and for the four most common cancer sites than those for Whites and African Americans. However, incidence and mortality rates for cancers of the uterine cervix, stomach, and liver are generally higher in minority than in White populations. Stomach and liver cancer incidence and mortality rates are more than twice as high as in Asian/Pacific Islanders than in Whites, reflecting increased exposure to infectious agents such as H pylori and hepatitis C.
Historical information to adjust for delays in reporting is not available for all racial and ethnic groups. From 1992 to 2000, delay-unadjusted incidence rates for all cancer sites combined decreased by 3.1% per year among American Indians/Alaskan Natives, by 1.0% per year in African Americans, by 0.6% among Whites, and by 0.5% among Asian/Pacific Islanders, whereas incidence rates stabilized among Hispanic-Latinos (data not shown). Similarly, the death rate from all cancers combined decreased annually from 1992 through 2000 by 1.5% per year in Asian/Pacific Islanders, 1.3% among African Americans, 0.9% among Whites, and 0.3% among Hispanic-Latinos, but it stabilized among American Indians/Alaskan Natives.3
Lifetime Probability of Developing Cancer
The lifetime probability of developing cancer is higher for men (45%) than for women (38%) (Table 10). However, because of breast cancer, women have a slightly higher probability of developing cancer before the age of 60. It is noteworthy that these estimates are based on the average experience of the general population. Thus they may overestimate or underestimate individual risk because of differences in exposure, family history, or both.
|
Cancer Survival Rates by Race
A poorer probability of survival once cancer is diagnosed contributes to the higher mortality rates among African-American men and women. African Americans are less likely than Whites to be diagnosed with cancer at a localized stage, when the disease may be more easily and successfully treated, and they are more likely to be diagnosed with cancer at a regional or distant stage. This is true for most of the common cancer sites (Figure 7). Furthermore, for nearly every cancer site, African Americans have lower five-year relative survival rates than do Whites at each stage of diagnosis (Figure 8), suggesting the possible influences of disparities in access and receipt of quality health care and of differences in comorbid conditions. The extent to which these factors, individually or collectively, contribute to the overall differential survival rate is not entirely clear.18 However, recent findings suggest that African Americans and Whites have similar disease outcomes when they receive similar cancer treatment and medical care.19
|
|
The relative five-year survival rates for most of the selected cancer sites and all cancer sites combined have improved notably over time (Table 11). This is true for both Whites and African Americans. Cancer sites without significant improvement in survival rates in the past 25 years include the uterine corpus, cervix, larynx, liver, lung, pancreas, stomach, and esophagus. For nearly all cancer sites, survival rates for African Americans remain substantially lower than survival rates for Whites.
|
The relative survival rate cannot be calculated for other racial and ethnic groups because accurate life expectancy data for these population subgroups are not available. However, based on cause-specific survival rates of persons with cancer from 1988 to 1997 in the SEER areas, most minority populations have an elevated probability of dying of cancer within five years of diagnosis, compared with non-Hispanic Whites after accounting for differences in age and stage at diagnosis.20 For most cancers, minority populations are also less likely to be diagnosed at a localized stage and more likely to be diagnosed at distant stage, compared with White populations. Based on all solid tumors diagnosed with stage information from 1996 to 2000 in the SEER areas, 30% of the cases among American Indians/Alaskan Natives, 26% in African Americans and Hispanic-Latinos, and 25% among Asian/Pacific Islanders were diagnosed at distant stage, compared with 22% in Whites.4,5
Cancer in Children
Cancer is the second leading cause of death among children between the ages of 1 and 14 years in the United States; accidents are the most frequent cause of death in this age group (Table 12). The most commonly occurring cancers found in children (0 to 14 years) are leukemia (particularly acute lymphocytic leukemia), tumors of the central and sympathetic nervous systems, lymphoma, soft tissue sarcomas, and renal tumors.3 In the past 25 years, the five-year relative survival rate has improved significantly for many childhood cancers, including non-Hodgkin lymphoma, acute lymphocytic leukemia, acute myeloid leukemia, and Wilms’ tumor (Table 13). The five-year relative survival rate among children for all cancer sites combined improved from 56% for patients diagnosed in 1974 to 1976 to 78% for those diagnosed in 1992 to 1999.3
|
|
|
STUDY LIMITATIONS AND FUTURE CHALLENGES |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSSELECTED FINDINGSSTUDY LIMITATIONS AND FUTURE...REFERENCES |
|---|
Despite these limitations, the American Cancer Society estimates do provide evidence of current patterns of cancer incidence and death in the United States. Such estimates will assist in continuing efforts to reduce the public health burden of cancer.
|
Footnotes |
|---|
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONMATERIALS AND METHODSSELECTED FINDINGSSTUDY LIMITATIONS AND FUTURE...REFERENCES |
|---|
This article has been cited by other articles:
|
|
 |
|
  S. Shirotake, E. Kikuchi, K. Matsumoto, S. Yazawa, T. Kosaka, A. Miyajima, K. Nakagawa, and M. Oya Role of Pelvic Lymph Node Dissection in Lymph Node-Negative Patients with Invasive Bladder Cancer Jpn. J. Clin. Oncol., March 1, 2010; 40(3): 247 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.-L. Tsai, B.-Y. Ho, and T.-M. Pan Red Mold Rice Mitigates Oral Carcinogenesis in 7,12-Dimethyl-1,2-Benz[a]anthracene-induced Oral Carcinogenesis in Hamster Evid. Based Complement. Altern. Med., December 17, 2009; (2009) nep215v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Fowler, G. R. Mundy, S. T. Lwin, C. C. Lynch, and C. M. Edwards A murine model of myeloma that allows genetic manipulation of the host microenvironment Dis. Model. Mech., November 1, 2009; 2(11-12): 604 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. GOERGENS, M. FRERICKS, and C. ESSER The Arylhydrocarbon Receptor Is Only Marginally Involved in the Antileukemic Effects of its Ligand Curcumin Anticancer Res, November 1, 2009; 29(11): 4657 - 4664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P. S. Crawford, H. Yang, K. R. Mattaini, and K. W. Hunter The Metastasis Efficiency Modifier Ribosomal RNA Processing 1 Homolog B (RRP1B) Is a Chromatin-associated Factor J. Biol. Chem., October 16, 2009; 284(42): 28660 - 28673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. SKAGIAS, E. POLITI, A. KARAMERIS, D. SAMBAZIOTIS, A. ARCHONDAKIS, A. NTINIS, I. MOREAS, O. VASOU, H. KOUTSELINI, and E. PATSOURIS Survivin Expression as a Strong Indicator of Recurrence in Urothelial Bladder Cancer. Predictive Value of Nuclear versus Cytoplasmic Staining Anticancer Res, October 1, 2009; 29(10): 4163 - 4167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. FABRINI, A. GADDUCCI, F. PERRONE, S. COSIO, C. LALISCIA, F. PASQUALETTI, S. GRESPI, and L. CIONINI Clinical Outcome of Tailored Adjuvant Postoperative Chemoradiotherapy in IB FIGO Stage Cervical Cancer Anticancer Res, October 1, 2009; 29(10): 4205 - 4210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. TAHARA, T. SHIBATA, M. NAKAMURA, H. YAMASHITA, D. YOSHIOKA, I. HIRATA, and T. ARISAWA RANTES Promoter Genotype and Gastric Cancer Risk in a Japanese Population Anticancer Res, October 1, 2009; 29(10): 4265 - 4269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. B. W. Wertheim, T. W. Yang, T.-c. Pan, A. Ramne, Z. Liu, H. P. Gardner, K. D. Dugan, P. Kristel, B. Kreike, M. J. van de Vijver, et al. The Snf1-related kinase, Hunk, is essential for mammary tumor metastasis PNAS, September 15, 2009; 106(37): 15855 - 15860. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Jang, A. Le Maitre, K. Ding, T. Winton, A. Bezjak, L. Seymour, F. A. Shepherd, and N. B. Leighl Quality-Adjusted Time Without Symptoms or Toxicity Analysis of Adjuvant Chemotherapy in Non-Small-Cell Lung Cancer: An Analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 Trial J. Clin. Oncol., September 10, 2009; 27(26): 4268 - 4273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. SERTZNIG, T. DUNLOP, M. SEIFERT, W. TILGEN, and J. REICHRATH Cross-talk between Vitamin D Receptor (VDR)- and Peroxisome Proliferator-activated Receptor (PPAR)-signaling in Melanoma Cells Anticancer Res, September 1, 2009; 29(9): 3647 - 3658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Dale "Staging the Aging" When Considering Androgen Deprivation Therapy for Older Men With Prostate Cancer J. Clin. Oncol., July 20, 2009; 27(21): 3420 - 3422. [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Azab, F. Azab, S. Blotta, C. M. Pitsillides, B. Thompson, J. M. Runnels, A. M. Roccaro, H. T. Ngo, M. R. Melhem, A. Sacco, et al. RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma Blood, July 16, 2009; 114(3): 619 - 629. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Miranda, M. K. Hassumi, M. C.M. Guimaraes, R. T. Simoes, T. G.A. Silva, R. C.P. Lira, A. M. Rocha, C. T. Mendes Jr., E. A. Donadi, C. P. Soares, et al. Galectin-3 Overexpression in Invasive Laryngeal Carcinoma, Assessed by Computer-assisted Analysis J. Histochem. Cytochem., July 1, 2009; 57(7): 665 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Buhmeida, R. Bendardaf, M. Hilska, J. Laine, Y. Collan, M. Laato, K. Syrjanen, and S. Pyrhonen PLA2 (group IIA phospholipase A2) as a prognostic determinant in stage II colorectal carcinoma Ann. Onc., July 1, 2009; 20(7): 1230 - 1235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. PROSCHEK, A. KURTH, P. PROSCHEK, T. J. VOGL, and M. G. MACK Prospective Pilot-study of Combined Bipolar Radiofrequency Ablation and Application of Bone Cement in Bone Metastases Anticancer Res, July 1, 2009; 29(7): 2787 - 2792. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Andrew, R. A. Mason, V. Memoli, and E. J. Duell Arsenic Activates EGFR Pathway Signaling in the Lung Toxicol. Sci., June 1, 2009; 109(2): 350 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. SOORIAKUMARAN, H. M. COLEY, S. B. FOX, P. MACANAS-PIRARD, D. P. LOVELL, A. HENDERSON, C. G. EDEN, P. D. MILLER, S. E.M. LANGLEY, and R. W. LAING A Randomized Controlled Trial Investigating the Effects of Celecoxib in Patients with Localized Prostate Cancer Anticancer Res, May 1, 2009; 29(5): 1483 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Lubbe, D. S. Zuzga, Z. Zhou, W. Fu, J. Pelta-Heller, R. J. Muschel, S. A. Waldman, and G. M. Pitari Guanylyl Cyclase C Prevents Colon Cancer Metastasis by Regulating Tumor Epithelial Cell Matrix Metalloproteinase-9 Cancer Res., April 15, 2009; 69(8): 3529 - 3536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. McFall, J. Ureda, T. L. Byrd, A. Valdes, P. Morales, D. B. Scott, D. Williams, J. Calderon-Mora, M. E. Casillas, and E. C. Y. Chan What is needed for informed decisions about prostate cancer screening: perspectives of African-American and Hispanic men Health Educ. Res., April 1, 2009; 24(2): 280 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Saidak, R. Mentaverri, and E. M. Brown The Role of the Calcium-Sensing Receptor in the Development and Progression of Cancer Endocr. Rev., April 1, 2009; 30(2): 178 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ychou, J.-L. Raoul, J.-Y. Douillard, S. Gourgou-Bourgade, R. Bugat, L. Mineur, F. Viret, Y. Becouarn, O. Bouche, E. Gamelin, et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802) Ann. Onc., April 1, 2009; 20(4): 674 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. KIM, K. ZUKOWSKI, and R. F. NOVAK Rapamycin Effects on mTOR Signaling in Benign, Premalignant and Malignant Human Breast Epithelial Cells Anticancer Res, April 1, 2009; 29(4): 1143 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. SOORIAKUMARAN, P. MACANAS-PIRARD, G. BUCCA, A. HENDERSON, S.E.M. LANGLEY, R.W. LAING, C.P. SMITH, E.E. LAING, and H.M. COLEY A Gene Expression Profiling Approach Assessing Celecoxib in a Randomized Controlled Trial in Prostate Cancer Cancer Genomics Proteomics, March 1, 2009; 6(2): 93 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kwon, S. Stephan, A. Mukhopadhyay, M. H. Muders, S. K. Dutta, J. S. Lau, and D. Mukhopadhyay Insulin Receptor Substrate-2 Mediated Insulin-like Growth Factor-I Receptor Overexpression in Pancreatic Adenocarcinoma through Protein Kinase C{delta} Cancer Res., February 15, 2009; 69(4): 1350 - 1357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-C. Hsieh, Y.-W. Cheng, C.-J. Lin, M.-C. Chou, C.-Y. Chen, and H. Lee Prognostic Significance of X-ray Cross-complementing Group 1 T-77C Polymorphism in Resected Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., February 1, 2009; 39(2): 81 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. F. Gilbert, C. P. Cannon, P. P. Lin, and V. O. Lewis Soft-tissue Sarcoma J. Am. Acad. Ortho. Surg., January 1, 2009; 17(1): 40 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. BUHMEIDA, M. HILSKA, A. ELZAGHEID, M. LAATO, Y. COLLAN, K. SYRJANEN, and S. PYRHONEN DNA Image Cytometry Predicts Disease Outcome in Stage II Colorectal Carcinoma Anticancer Res, January 1, 2009; 29(1): 99 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Blum, T. Koyama, A. E. M'Koma, J. M. Iturregui, M. Martinez-Ferrer, C. Uwamariya, J. A. Smith Jr., P. E. Clark, and N. A. Bhowmick Chemokine Markers Predict Biochemical Recurrence of Prostate Cancer following Prostatectomy Clin. Cancer Res., December 1, 2008; 14(23): 7790 - 7797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. R. Qin, H.-J. Kim, J.-Y. Kim, E. M. Hurt, G. J. Klarmann, B. T. Kawasaki, M. A. Duhagon Serrat, and W. L. Farrar Activation of Signal Transducer and Activator of Transcription 3 through a Phosphomimetic Serine 727 Promotes Prostate Tumorigenesis Independent of Tyrosine 705 Phosphorylation Cancer Res., October 1, 2008; 68(19): 7736 - 7741. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Bailey, B. J. Swanson, T. Hamada, J. P. Eggers, P. K. Singh, T. Caffery, M. M. Ouellette, and M. A. Hollingsworth Sonic Hedgehog Promotes Desmoplasia in Pancreatic Cancer Clin. Cancer Res., October 1, 2008; 14(19): 5995 - 6004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Knab, J. K. Salama, A. Solanki, K. M. Stenson, E. E. Cohen, M. E. Witt, D. J. Haraf, and E. E. Vokes Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma Ann. Onc., September 1, 2008; 19(9): 1650 - 1654. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Eiblmaier, L. A. Meyer, M. A. Watson, P. M. Fracasso, L. J. Pike, and C. J. Anderson Correlating EGFR Expression with Receptor-Binding Properties and Internalization of 64Cu-DOTA-Cetuximab in 5 Cervical Cancer Cell Lines J. Nucl. Med., September 1, 2008; 49(9): 1472 - 1479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A Gilchrest Sun exposure and vitamin D sufficiency Am. J. Clinical Nutrition, August 1, 2008; 88(2): 570S - 577S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Pitari, J. E. Lin, F. J. Shah, W. J. Lubbe, D. S. Zuzga, P. Li, S. Schulz, and S. A. Waldman Enterotoxin preconditioning restores calcium-sensing receptor-mediated cytostasis in colon cancer cells Carcinogenesis, August 1, 2008; 29(8): 1601 - 1607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Masciullo, E. Berardengo, A. Boglione, A. Sgambato, A. Bernardi, M. Forni, A. Linari, L. Cito, G. Scambia, A. Comandone, et al. The Retinoblastoma Family Member pRb2/p130 Is an Independent Predictor of Survival in Human Soft Tissue Sarcomas Clin. Cancer Res., August 1, 2008; 14(15): 4775 - 4779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lu, H. Xiao, H. You, Y. Lin, H. Jin, B. Snagaski, and C. S. Yang Synergistic Inhibition of Lung Tumorigenesis by a Combination of Green Tea Polyphenols and Atorvastatin Clin. Cancer Res., August 1, 2008; 14(15): 4981 - 4988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Summers, L. R. Handwerker, P. J. Pickhardt, R. L. Van Uitert, K. K. Deshpande, S. Yeshwant, J. Yao, and M. Franaszek Performance of a Previously Validated CT Colonography Computer-Aided Detection System in a New Patient Population Am. J. Roentgenol., July 1, 2008; 191(1): 168 - 174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Psyrri, P. Kountourakis, A. Scorilas, S. Markakis, R. Camp, D. Kowalski, E. P. Diamandis, and M. A. Dimopoulos Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression Ann. Onc., July 1, 2008; 19(7): 1271 - 1277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. R. Placencio, A.-R. Sharif-Afshar, X. Li, H. Huang, C. Uwamariya, E. G. Neilson, M. M. Shen, R. J. Matusik, S. W. Hayward, and N. A. Bhowmick Stromal Transforming Growth Factor-{beta} Signaling Mediates Prostatic Response to Androgen Ablation by Paracrine Wnt Activity Cancer Res., June 15, 2008; 68(12): 4709 - 4718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ralhan, L. V. DeSouza, A. Matta, S. Chandra Tripathi, S. Ghanny, S. Datta Gupta, S. Bahadur, and K. W. M. Siu Discovery and Verification of Head-and-neck Cancer Biomarkers by Differential Protein Expression Analysis Using iTRAQ Labeling, Multidimensional Liquid Chromatography, and Tandem Mass Spectrometry Mol. Cell. Proteomics, June 1, 2008; 7(6): 1162 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kitajima, K. Murakami, E. Yamasaki, I. Fukasawa, N. Inaba, Y. Kaji, and K. Sugimura Accuracy of 18F-FDG PET/CT in Detecting Pelvic and Paraaortic Lymph Node Metastasis in Patients with Endometrial Cancer Am. J. Roentgenol., June 1, 2008; 190(6): 1652 - 1658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vicent, D. Luis-Ravelo, I. Anton, I. Garcia-Tunon, F. Borras-Cuesta, J. Dotor, J. De Las Rivas, and F. Lecanda A Novel Lung Cancer Signature Mediates Metastatic Bone Colonization by a Dual Mechanism Cancer Res., April 1, 2008; 68(7): 2275 - 2285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Cotton, M. K. O'Bryan, and B. T. Hinton Cellular Signaling by Fibroblast Growth Factors (FGFs) and Their Receptors (FGFRs) in Male Reproduction Endocr. Rev., April 1, 2008; 29(2): 193 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Takei, Y. Saga, H. Mizukami, T. Takayama, M. Ohwada, K. Ozawa, and M. Suzuki Overexpression of PTEN in ovarian cancer cells suppresses i.p. dissemination and extends survival in mice Mol. Cancer Ther., March 1, 2008; 7(3): 704 - 711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Fletcher, B. Djulbegovic, H. P. Soares, B. A. Siegel, V. J. Lowe, G. H. Lyman, R. E. Coleman, R. Wahl, J. C. Paschold, N. Avril, et al. Recommendations on the Use of 18F-FDG PET in Oncology J. Nucl. Med., March 1, 2008; 49(3): 480 - 508. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Steinert, M. Hantschick, M. Vieth, I. Gastinger, F. Kuhnel, H. Lippert, and M. A. Reymond Influence of Subclinical Tumor Spreading on Survival After Curative Surgery for Colorectal Cancer Arch Surg, February 1, 2008; 143(2): 122 - 128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Dubinsky, C. Cuevas, M. K. Dighe, O. Kolokythas, and J. H. Hwang High-Intensity Focused Ultrasound: Current Potential and Oncologic Applications Am. J. Roentgenol., January 1, 2008; 190(1): 191 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. H. Pharo Optimizing Living With Cancer Pain J Am Osteopath Assoc, December 1, 2007; 107(suppl_7): ES1 - ES2. [Full Text] [PDF]
|
|
|
|
|
|
D. -W. Kim, S. -Y. Kim, H. -K. Kim, S. -W. Kim, S. W. Shin, J. S. Kim, K. Park, M. Y. Lee, and D. S. Heo Multicenter phase II trial of Genexol-PM, a novel Cremophor-free, polymeric micelle formulation of paclitaxel, with cisplatin in patients with advanced non-small-cell lung cancer Ann. Onc., December 1, 2007; 18(12): 2009 - 2014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Gallagher, M. Capanu, G. Raggio, and N. Kemeny Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis Ann. Onc., December 1, 2007; 18(12): 1995 - 1999. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. H. Pharo and L. Zhou Controlling Cancer Pain With Pharmacotherapy J Am Osteopath Assoc, December 1, 2007; 107(suppl_7): ES22 - ES32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Li, J. E. Lin, I. Chervoneva, S. Schulz, S. A. Waldman, and G. M. Pitari Homeostatic Control of the Crypt-Villus Axis by the Bacterial Enterotoxin Receptor Guanylyl Cyclase C Restricts the Proliferating Compartment in Intestine Am. J. Pathol., December 1, 2007; 171(6): 1847 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-M. Boller and H. Nelson Colon and Rectal Cancer: Laparoscopic or Open? Clin. Cancer Res., November 15, 2007; 13(22): 6894s - 6896s. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-L. Monin, M. Monchi, M. E.W. Kirsch, H. Petit-Eisenmann, S. Baleynaud, C. Chauvel, D. Metz, C. Adams, J.-P. Quere, P. Gueret, et al. Low-gradient aortic stenosis: impact of prosthesis-patient mismatch on survival Eur. Heart J., November 1, 2007; 28(21): 2620 - 2626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liu, H. G. Vikis, Y. Yi, M. Futamura, Y. Wang, and M. You Degradation of Lung Adenoma Susceptibility 1, a Major Candidate Mouse Lung Tumor Modifier, Is Required for Cell Cycle Progression Cancer Res., November 1, 2007; 67(21): 10207 - 10213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Kulasingam and E. P. Diamandis Proteomics Analysis of Conditioned Media from Three Breast Cancer Cell Lines: A Mine for Biomarkers and Therapeutic Targets Mol. Cell. Proteomics, November 1, 2007; 6(11): 1997 - 2011. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. N. Kolar, R. Barhoumi, E. S. Callaway, Y.-Y. Fan, N. Wang, J. R. Lupton, and R. S. Chapkin Synergy between docosahexaenoic acid and butyrate elicits p53-independent apoptosis via mitochondrial Ca2+ accumulation in colonocytes Am J Physiol Gastrointest Liver Physiol, November 1, 2007; 293(5): G935 - G943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Oudard, E. Banu, F. Scotte, A. Banu, J. Medioni, P. Beuzeboc, F. Joly, J.-M. Ferrero, F. Goldwasser, and J.-M. Andrieu Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients Ann. Onc., November 1, 2007; 18(11): 1828 - 1833. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Mueller, F. A. Goumas, M. Affeldt, S. Sandtner, U. M. Gehling, S. Brilloff, J. Walter, N. Karnatz, K. Lamszus, X. Rogiers, et al. Stromal Fibroblasts in Colorectal Liver Metastases Originate From Resident Fibroblasts and Generate an Inflammatory Microenvironment Am. J. Pathol., November 1, 2007; 171(5): 1608 - 1618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Lyshchik, S. B. Hobbs, A. C. Fleischer, D. Khabele, D.-S. Son, J. C. Gore, and R. R. Price Ovarian Volume Measurements in Mice With High-Resolution Ultrasonography J. Ultrasound Med., October 1, 2007; 26(10): 1419 - 1425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lapointe, C. Li, C. P. Giacomini, K. Salari, S. Huang, P. Wang, M. Ferrari, T. Hernandez-Boussard, J. D. Brooks, and J. R. Pollack Genomic Profiling Reveals Alternative Genetic Pathways of Prostate Tumorigenesis Cancer Res., September 15, 2007; 67(18): 8504 - 8510. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhang, J. Huang, N. Yang, J. Greshock, S. Liang, K. Hasegawa, A. Giannakakis, N. Poulos, A. O'Brien-Jenkins, D. Katsaros, et al. Integrative Genomic Analysis of Phosphatidylinositol 3'-Kinase Family Identifies PIK3R3 as a Potential Therapeutic Target in Epithelial Ovarian Cancer Clin. Cancer Res., September 15, 2007; 13(18): 5314 - 5321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Steger, T. Walles, T. Walker, and G. Friedel Long-term follow-up of thoracoscopic talc pleurodesis for primary spontaneous pneumothorax Eur. Respir. J., September 1, 2007; 30(3): 598 - 599. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Klotz Point: Active Surveillance for Favorable Risk Prostate Cancer J Natl Compr Canc Netw, August 1, 2007; 5(7): 693 - 698. [Abstract] [PDF]
|
|
|
|
 |
|
 T. Rago, F. Santini, M. Scutari, A. Pinchera, and P. Vitti Elastography: New Developments in Ultrasound for Predicting Malignancy in Thyroid Nodules J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 2917 - 2922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Mosley, J. T. Poirier, D. D. Seachrist, M. D. Landis, and R. A. Keri Rapamycin inhibits multiple stages of c-Neu/ErbB2 induced tumor progression in a transgenic mouse model of HER2-positive breast cancer Mol. Cancer Ther., August 1, 2007; 6(8): 2188 - 2197. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A Kuehle, J. Langhorst, S. C Ladd, T. Zoepf, M. Nuefer, F. Grabellus, J. Barkhausen, G. Gerken, and T. C Lauenstein Magnetic resonance colonography without bowel cleansing: a prospective cross sectional study in a screening population Gut, August 1, 2007; 56(8): 1079 - 1085. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Erythematous Papules and Plaques Involving the Groin and Scrotum Diagnosis Arch Dermatol, August 1, 2007; 143(8): 1067 - 1072. [Full Text] [PDF]
|
|
|
|
|
|
Z. Zhao, Y. Xiao, P. Elson, H. Tan, S. J. Plummer, M. Berk, P. P. Aung, I. C. Lavery, J. P. Achkar, L. Li, et al. Plasma Lysophosphatidylcholine Levels: Potential Biomarkers for Colorectal Cancer J. Clin. Oncol., July 1, 2007; 25(19): 2696 - 2701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Caron, G. Choquet-Kastylevsky, and R. Joubert-Caron Cancer Immunomics Using Autoantibody Signatures for Biomarker Discovery Mol. Cell. Proteomics, July 1, 2007; 6(7): 1115 - 1122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.A. Lane, G.Y.H. Lip, and D.G. Beevers Ethnic differences in cancer incidence and mortality: the Birmingham Factory Screening Project QJM, July 1, 2007; 100(7): 423 - 431. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Lamy, S. Roussi, M. Chaabi, F. Gosse, N. Schall, A. Lobstein, and F. Raul Chemopreventive effects of lupulone, a hop {beta}-acid, on human colon cancer-derived metastatic SW620 cells and in a rat model of colon carcinogenesis Carcinogenesis, July 1, 2007; 28(7): 1575 - 1581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Kademani Oral Cancer Mayo Clin. Proc., July 1, 2007; 82(7): 878 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Veit-Haibach, G Antoch, T Beyer, H Stergar, R Schleucher, E A M Hauth, and A Bockisch FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy Br. J. Radiol., July 1, 2007; 80(955): 508 - 515. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhu, G. Shi, C. Max. Schmidt, R. H. Hruban, and S. F. Konieczny Acinar Cells Contribute to the Molecular Heterogeneity of Pancreatic Intraepithelial Neoplasia Am. J. Pathol., July 1, 2007; 171(1): 263 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kiziltepe, T. Hideshima, L. Catley, N. Raje, H. Yasui, N. Shiraishi, Y. Okawa, H. Ikeda, S. Vallet, S. Pozzi, et al. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells Mol. Cancer Ther., June 1, 2007; 6(6): 1718 - 1727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J-C Eymard, F Priou, A Zannetti, A Ravaud, D Lepille, P Kerbrat, P Gomez, B Paule, D Genet, P Herait, et al. Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer Ann. Onc., June 1, 2007; 18(6): 1064 - 1070. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Tooker, W.-C. Yen, S.-C. Ng, A. Negro-Vilar, and T. W. Hermann Bexarotene (LGD1069, Targretin), a Selective Retinoid X Receptor Agonist, Prevents and Reverses Gemcitabine Resistance in NSCLC Cells by Modulating Gene Amplification Cancer Res., May 1, 2007; 67(9): 4425 - 4433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Welm, J. B. Sneddon, C. Taylor, D. S. A. Nuyten, M. J. van de Vijver, B. H. Hasegawa, and J. M. Bishop The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans PNAS, May 1, 2007; 104(18): 7570 - 7575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Giantonio, P. J. Catalano, N. J. Meropol, P. J. O'Dwyer, E. P. Mitchell, S. R. Alberts, M. A. Schwartz, and A. B. Benson III Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 J. Clin. Oncol., April 20, 2007; 25(12): 1539 - 1544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Gatzemeier, A. Pluzanska, A. Szczesna, E. Kaukel, J. Roubec, F. De Rosa, J. Milanowski, H. Karnicka-Mlodkowski, M. Pesek, P. Serwatowski, et al. Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non-Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial J. Clin. Oncol., April 20, 2007; 25(12): 1545 - 1552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Pepe, B. Hasan, T. L. Winton, L. Seymour, B. Graham, R. B. Livingston, D. H. Johnson, J. R. Rigas, K. Ding, and F. A. Shepherd Adjuvant Vinorelbine and Cisplatin in Elderly Patients: National Cancer Institute of Canada and Intergroup Study JBR.10 J. Clin. Oncol., April 20, 2007; 25(12): 1553 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Psyrri, P Kountourakis, Z Yu, C Papadimitriou, S Markakis, R. Camp, T Economopoulos, and M. Dimopoulos Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets Ann. Onc., April 1, 2007; 18(4): 709 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. del Carmen, E. F. Halpern, D. B. Kopans, B. Moy, R. H. Moore, P. E. Goss, and K. S. Hughes Mammographic Breast Density and Race Am. J. Roentgenol., April 1, 2007; 188(4): 1147 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Shor, E. A. Keschman, F. Y. Lee, C. Muro-Cacho, G. D. Letson, J. C. Trent, W. J. Pledger, and R. Jove Dasatinib Inhibits Migration and Invasion in Diverse Human Sarcoma Cell Lines and Induces Apoptosis in Bone Sarcoma Cells Dependent on Src Kinase for Survival Cancer Res., March 15, 2007; 67(6): 2800 - 2808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Menon, D. R. Soto-Pantoja, M. F. Callahan, J. M. Cline, C. M. Ferrario, E. A. Tallant, and P. E. Gallagher Angiotensin-(1-7) Inhibits Growth of Human Lung Adenocarcinoma Xenografts in Nude Mice through a Reduction in Cyclooxygenase-2 Cancer Res., March 15, 2007; 67(6): 2809 - 2815. [Abstract] [Full Text] [PDF]
|
|
Read all eLetters
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | COVER ARCHIVE | SEARCH | TABLE OF CONTENTS |
